Clinical Diagnostics Leverage CombiMatrix’s established cytogenetic and cytogenomic testing capabilities for prenatal diagnosis, miscarriage analysis, and PGD/PGS to offer expanded diagnostic panels or bundled testing services for obstetrics clinics, fertility centers, and IVF networks.

Expansion Readiness Target clinics and laboratories seeking scale in genetic testing by proposing outsourced testing partnerships, establishing referral agreements, or migrating to CombiMatrix’s full-service cytogenomics platform to increase capacity and reduce turnaround times.

Genomic Innovations Position SNP microarray and high-resolution karyotyping capabilities as differentiators for complex fetal diagnostics; upsell advanced chromosomal analysis services to pediatric and prenatal care providers addressing developmental disorders with molecular precision.

Strategic Partnerships Explore collaboration with IVF centers and fertility networks for PGD/PGS workflow integration, co-marketing opportunities, and joint service offerings to capture a larger share of the preimplantation genetic testing market.

Financial & Growth Signals With a mid-market revenue footprint and historical M&A activity, approach potential acquirers or investors with a narrative of proven diagnostic expertise and scalable cytogenomics operations, while offering service-based revenue through regulated clinical testing.